{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:09:09Z","timestamp":1792440549659,"version":"4.5.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To determine the effect of CYP2D6 metabolizer status on aripiprazole tolerability in pediatric patients with mood disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively reviewed electronic medical record data for 277 patients \u226418 years of age (at the time of CYP2D6 testing) with a mood disorder, receiving oral aripiprazole, and CYP2D6 genotyped as part of routine care. The maximum aripiprazole dose and concomitant medications were extracted from the medical record. The reason for aripiprazole discontinuation was determined to be from side effects (e.g., weight gain, akathisia, GI upset), nonresponse, or other reasons (e.g., financial). Associations with CYP2D6 were analyzed using multivariate linear regression models and chi-square tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 277 patients (mean age: 14.3\u2009\u00b1\u20092.4), 57% were normal metabolizers (NMs), 37% were intermediate metabolizers (IMs), 5% were poor metabolizers (PMs), and 1.4% were ultrarapid metabolizers (UMs). A total of 72.2% of the cohort were concomitantly taking a CYP2D6 inhibitor, resulting in phenoconversion. Accounting for phenoconversion resulted in 27% phenoconverted NMs (pNMs), 24% phenoconverted IMs (pIMs), 48% phenoconverted PMs (pPMs), and &lt;1% phenoconverted ultrarapid metabolizers. CYP2D6 pPMs discontinued treatment due to side effects more often than any other CYP2D6 group (67% for pPM, 51% pIM, 57% pNM, chi-square\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.024). Body mass index percentile change was associated with the CYP2D6 phenotype (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.038), the time on aripiprazole (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.001), and the number of concomitant CYP2D6 substrates (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.044) in multivariable models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Phenoconverted CYP2D6 metabolizer status is associated with aripiprazole discontinuation. In addition, dose adjustments based on CYP2D6 metabolizer status and concomitant medications could improve aripiprazole treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2020.0058","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T13:45:11Z","timestamp":1598449511000},"page":"56-62","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":18,"title":["CYP2D6 Phenotype Influences Aripiprazole Tolerability in Pediatric Patients with Mood Disorders"],"prefix":"10.1177","volume":"31","author":[{"given":"Sahar A.","family":"Jallaq","sequence":"first","affiliation":[{"name":"Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."},{"name":"Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Verba","sequence":"additional","affiliation":[{"name":"Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."},{"name":"Department of Molecular, Cellular, and Biochemical Pharmacology, University of Cincinnati, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, and University of Cincinnati, Cincinnati, Ohio, USA."},{"name":"Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."},{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."},{"name":"Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa P.","family":"DelBello","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Neuroscience, and University of Cincinnati, Cincinnati, Ohio, USA."},{"name":"Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Division of Research in Patient Services, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."},{"name":"Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA."},{"name":"Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,11]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0511-9"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12960"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.87"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12692"},{"key":"e_1_3_2_6_1","unstructured":"CDER FDA: Highlights of Prescribing Information for Abilify. Otsuka Pharmaceutical Co. Ltd. Tokyo 2014."},{"key":"e_1_3_2_7_1","unstructured":"CDER FDA: Highlights of Prescribing Information. Lilly USA LLC Indianapolis IN USA 2020."},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2016.18.3\/jbishop"},{"key":"e_1_3_2_9_1","first-page":"1","article-title":"Table of Pharmacogenomic Biomarkers in Drug Labeling | FDA","author":"Federal Drug Administration","year":"2019","unstructured":"Federal Drug Administration: Table of Pharmacogenomic Biomarkers in Drug Labeling | FDA. United States Gov , 1\u201353, 2019.","journal-title":"United States Gov"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.11m07104"},{"key":"e_1_3_2_11_1","unstructured":"Flockhart DA: Cytochrome P450 drug interaction table\u2014Drug Interactions 2020."},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8020015"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200215666140202215316"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30088-4"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0037"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(96)00779-X"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1643"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.12m07807"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1165"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.279"},{"key":"e_1_3_2_21_1","article-title":"Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6\u201317 years old): Results from a pooled analysis of 2 studies","volume":"13","author":"Robb AS","year":"2011","unstructured":"Robb AS, , Andersson C, , Bellocchio EE, , Manos G, , Rojas-Fernandez C, , Mathew S, , Marcus R, , Owen R, , Mankoski R: Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6\u201317 years old): Results from a pooled analysis of 2 studies. Prim Care Companion J Clin Psychiatry, 13, PCC.10m01008, 2011.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0431-8"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-015-0591-z"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2020.0058","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0058","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2020.0058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:55:56Z","timestamp":1777388156000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2020.0058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1089\/cap.2020.0058"],"URL":"https:\/\/doi.org\/10.1089\/cap.2020.0058","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}